MENU

Create Your Most
Valuable Plan

Multiple myeloma is a complex disease that can require planning and a team effort to navigate. Your Myeloma MVP – your Most Valuable Plan – is designed to help you consider and communicate your goals and priorities to your healthcare team.

Start building your plan

Thank you!

We look forward to sharing updates in the future

Close window

Sign up to learn more and receive
updates from Myeloma Explained.

References

  1. National Cancer Institute. Cancer Stat Facts: Myeloma. Available at: https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed on: September 11, 2019.
  2. Ailawadhi S, Swaika A, Advani P, et al. Current State of Patient Awareness and Participation in Care for Multiple Myeloma and the Psychophysical Impact of Treatment: An International Internet-Based Study. Blood. 2014;124:1294.
  3. Jakubowiak A. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. Semin in Hematol. 2012;49 (Suppl 1):S16-S32.
  4. American Cancer Society. About Multiple Myeloma. Available at: https://www.cancer.org/content/dam/CRC/PDF/Public/8738.00.pdf. Accessed on: September 11, 2019.
  5. Multiple Myeloma Research Foundation. Multiple Myeloma Disease Overview. Available at: https://www.themmrf.org/wp-content/uploads/MMRF_Disease_Overview.pdf. Accessed on: September 11, 2019.
  6. American Cancer Society. Signs and Symptoms of Multiple Myeloma. Available at: https://www.cancer.org/cancer/multiple-myeloma/detection-diagnosis-staging/signs-symptoms.html. Accessed on: September 11, 2019.
  7. American Cancer Society. Risk Factors for Multiple Myeloma. Available at: https://www.cancer.org/cancer/multiple-myeloma/causes-risks-prevention/risk-factors.html. Accessed on: September 11, 2019.
  8. National Cancer Institute. Understanding Cancer Prognosis. Available at: https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis. Accessed on: September 11, 2019.
  9. Laubach J, Garderet L, Mahindra A, et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2015; 30(5):1005-17.
  10. Durie BGM. MM Concise Review - 2017. Available at: www.myeloma.org. Accessed on: September 6, 2019.
  11. American Cancer Society. Drug Therapy for Multiple Myeloma. Available at: https://www.cancer.org/cancer/multiple-myeloma/treating/chemotherapy.html. Accessed on: September 6, 2019.
  12. MMRF. Treatment Overview. Available at: https://www.mmrf.org/wp-content/uploads/MMRF_Brochure_Treatment-Overview_092017.pdf. Accessed on: September 24, 2019.
  13. Multiple Myeloma Research Foundation. Standard Treatments. Available at: https://themmrf.org/multiple-myeloma/treatment-options/standard-treatments/. Accessed on: September 6, 2019.
  14. Quach H, Ritchie D, Stewart SK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1): 22-32.
  15. Terpos E, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31(18):2347-57.
  16. American Cancer Society. What is Multiple Myeloma? Available at: https://www.cancer.org/content/dam/CRC/PDF/Public/8738.00.pdf. Accessed on: September 11, 2019.
  17. NIH. Iron-Deficiency Anemia. www.nhlbi.nih.gov. Accessed on: September 6, 2019.
  18. Bhowmik D, et al. Prevalence Of Renal Impairment In Patients With Multiple Myeloma: Analysis Of Real-World Database. Journal of the International Society for Pharmacoeconomic and Outcomes Research. 2016;9(3):A141.
  19. Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100 (1) 107-113.

You are now leaving MyelomaExplained.com and going to a website.

Would you like to proceed?

YesCancel

You are now leaving MyelomaExplained.com.

Amgen does not influence, control, or endorse the content on the site you are about to enter. Would you like to proceed?

YesCancel